These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 15449905)
21. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. Beale KK; Robinson WE Antiviral Res; 2000 Jun; 46(3):223-32. PubMed ID: 10867160 [TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Le Tiec C; Barrail A; Goujard C; Taburet AM Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117 [TBL] [Abstract][Full Text] [Related]
23. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. Pham HT; Mesplède T; Wainberg MA Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466 [TBL] [Abstract][Full Text] [Related]
24. HIV-1 integrase and RNase H activities as therapeutic targets. Andréola ML; De Soultrait VR; Fournier M; Parissi V; Desjobert C; Litvak S Expert Opin Ther Targets; 2002 Aug; 6(4):433-46. PubMed ID: 12223059 [TBL] [Abstract][Full Text] [Related]
25. New developments in anti-HIV chemotherapy. De Clercq E Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282 [TBL] [Abstract][Full Text] [Related]
27. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. De Clercq E Rev Med Virol; 2000; 10(4):255-77. PubMed ID: 10891872 [TBL] [Abstract][Full Text] [Related]
29. New targets and new drugs in the treatment of HIV. López-Aldeguer J; Aguirrebengoa K; Arribas JR; Esté JA; Kindelán JM Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():25-40. PubMed ID: 16373002 [TBL] [Abstract][Full Text] [Related]
30. Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase. de Soultrait VR; Desjobert C; Tarrago-Litvak L Curr Med Chem; 2003 Sep; 10(18):1765-78. PubMed ID: 12871103 [TBL] [Abstract][Full Text] [Related]
31. An update and review of antiretroviral therapy. Piacenti FJ Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488 [TBL] [Abstract][Full Text] [Related]
32. Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments. Gill MSA; Hassan SS; Ahemad N Eur J Med Chem; 2019 Oct; 179():423-448. PubMed ID: 31265935 [TBL] [Abstract][Full Text] [Related]
33. Newer antiretroviral agents and how to use them. Kim HH; Daar ES Curr HIV/AIDS Rep; 2009 May; 6(2):55-62. PubMed ID: 19358775 [TBL] [Abstract][Full Text] [Related]
34. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher? Garbelli A; Riva V; Crespan E; Maga G Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620 [TBL] [Abstract][Full Text] [Related]
35. SHIVA - a web application for drug resistance and tropism testing in HIV. Riemenschneider M; Hummel T; Heider D BMC Bioinformatics; 2016 Aug; 17(1):314. PubMed ID: 27549230 [TBL] [Abstract][Full Text] [Related]
36. Atazanavir/ritonavir: a review of its use in HIV therapy. von Hentig N Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089 [TBL] [Abstract][Full Text] [Related]
37. New antiretroviral agents. Gallant JE Hopkins HIV Rep; 2001 Mar; 13(2):2, 16. PubMed ID: 12184261 [No Abstract] [Full Text] [Related]
38. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM; J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627 [TBL] [Abstract][Full Text] [Related]
39. Combinatorial chemistry as a tool for targeting different stages of the replicative HIV-1 cycle. Mugnaini C; Petricci E; Corelli F; Botta M Comb Chem High Throughput Screen; 2005 Aug; 8(5):387-401. PubMed ID: 16101579 [TBL] [Abstract][Full Text] [Related]
40. Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors. Contreras-Galindo R; Dube D; Fujinaga K; Kaplan MH; Markovitz DM J Virol; 2017 Dec; 91(23):. PubMed ID: 28931682 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]